Deferasirox, a novel iron chelator, with gemcitabine inhibits pancreatic cancer cell growth in vitro and in vivo

被引：0
|
作者：
Shinoda, Shuhei [1 ]
Takami, Taro [1 ]
Yamasaki, Takahiro [2 ]
Sakaida, Isao [1 ]
机构：
[1] Yamaguchi Univ, Sch Med, Dept Gastroenterol & Hepatol, Yamaguchi, Yamaguchi, Japan
[2] Yamaguchi Univ, Sch Med, Dept Oncol & Lab Med, Yamaguchi, Yamaguchi, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-2040
引用
收藏
页码：753 / 753
页数：1
相关论文
共 50 条
  • [1] DEFERASIROX (DFX), A NEWLY ORAL IRON CHELATOR, WITH GEMCITABINE (GEM) INHIBITED PANCREATIC CANCER CELL PROLIFERATION AND INDUCED APOPTOSIS IN VITRO AND IN VIVO
    Shinoda, Shuhei
    Kaino, Seiji
    Amano, Shogo
    Matsumoto, Toshihiko
    Fujisawa, Koichi
    Takami, Taro
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Sakaida, Isao
    GASTROENTEROLOGY, 2017, 152 (05) : S273 - S274
  • [2] Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
    Hirofumi Harima
    Seiji Kaino
    Taro Takami
    Shuhei Shinoda
    Toshihiko Matsumoto
    Koichi Fujisawa
    Naoki Yamamoto
    Takahiro Yamasaki
    Isao Sakaida
    BMC Cancer, 16
  • [3] Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
    Harima, Hirofumi
    Kaino, Seiji
    Takami, Taro
    Shinoda, Shuhei
    Matsumoto, Toshihiko
    Fujisawa, Koichi
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Sakaida, Isao
    BMC CANCER, 2016, 16
  • [4] Deferasirox, a Newly Developed Oral Iron Chelator, Showing Antiproliferative Activity Against Pancreatic Cancer In Vitro and In Vivo
    Harima, Hirofumi
    Kaino, Seiji
    Shinoda, Shuhei
    Matsumoto, Toshihiko
    Fujisawa, Koichi
    Takami, Taro
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Sakaida, Isao
    GASTROENTEROLOGY, 2016, 150 (04) : S329 - S330
  • [5] The oral iron chelator, deferasirox, may be a novel potential therapeutic agent for pancreatic cancer
    Harima, Hirofumi
    Kaino, Seiji
    Shinoda, Shuhei
    Kawano, Michitaka
    Suenaga, Shigeyuki
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Sakaida, Isao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 34 - 34
  • [6] IN VITRO AND IN VIVO EFFECT OF AN ORAL IRON CHELATOR DEFERASIROX IN MYELOID LEUKEMIA CELLS
    Choi, C. W.
    Kim, J. L.
    Kang, H. N.
    Kang, M. H.
    Yoo, Y. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 268 - 268
  • [7] Curcurnin inhibits in vitro and in vivo pancreatic cancer cell growth and tumor xenografts
    Alonso, Juan diego
    Subramaniam, Dharmalingam
    May, Randal
    Linehan, David
    Ramanujam, Rama P.
    Houchen, Courtney W.
    Anant, Shrikant
    GASTROENTEROLOGY, 2007, 132 (04) : A436 - A436
  • [8] In vitro antimyeloma activity of the iron chelator deferasirox (DFX).
    Willenbacher, Ella
    Willenbacher, Wolfgang
    Funk, Ulrike
    Kircher, Brigitte
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo
    Ford, S. J.
    Obeidy, P.
    Lovejoy, D. B.
    Bedford, M.
    Nichols, L.
    Chadwick, C.
    Tucker, O.
    Lui, G. Y. L.
    Kalinowski, D. S.
    Jansson, P. J.
    Iqbal, T. H.
    Alderson, D.
    Richardson, D. R.
    Tselepis, C.
    BRITISH JOURNAL OF PHARMACOLOGY, 2013, 168 (06) : 1316 - 1328
  • [10] CLPP AGONIST INHIBITS PANCREATIC CANCER GROWTH IN VITRO AND IN VIVO
    LaComb, Joseph F.
    Giarrizzo, Michael
    Mojumdar, Aisharja
    Patel, Hetvi R.
    Graves, Lee
    Iwanowicz, Edwin
    Bialkowska, Agnieszka B.
    GASTROENTEROLOGY, 2023, 164 (06) : S326 - S326
12345